Jounce Therapeutics, Inc.
JNCE · NASDAQ
12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | 0.02 | -0.10 | 0.03 | -0.02 |
| FCF Yield | -51.95% | -20.12% | -11.24% | -10.77% |
| EV / EBITDA | 1.66 | -3.68 | -2.60 | 4.83 |
| Quality | ||||
| ROIC | -27.12% | -38.35% | -19.78% | 27.15% |
| Gross Margin | 100.00% | 100.00% | 100.00% | 100.00% |
| Cash Conversion Ratio | 0.57 | 0.92 | 0.63 | -0.53 |
| Growth | ||||
| Revenue 3-Year CAGR | 9.57% | -43.33% | -1.49% | 27.32% |
| Free Cash Flow Growth | 64.47% | -200.79% | 10.39% | 52.11% |
| Safety | ||||
| Net Debt / EBITDA | 2.80 | 0.90 | 2.89 | -0.63 |
| Interest Coverage | 0.00 | 0.00 | 0.00 | 0.00 |
| Efficiency | ||||
| Inventory Turnover | 0.00 | 0.00 | 0.00 | 0.00 |
| Cash Conversion Cycle | 0.00 | 0.00 | 0.00 | 0.00 |